

Development and Validation of Alternative Methods

Sharon Munn

Alternative Methods and ECVAM
The Institute for Health and Consumer Protection (IHCP)
Science for a healthier life



OUTLINE

- **History**
- Validation principles
- Successes and next challenges
- ECVAM Role


Two British scientists, Bill Russell and Rex Burch introduced the “3Rs” as a framework for considering the humane use of animals.




Refine



Reduce



Replace



86/609/EEC

*Russell, W. M. S. and Burch, R. L. 1959. The principles of humane experimental technique
Special Edition, Universities Federation for Animal Welfare, Potters Bar, England*

ECVAM

- Founded in 1991 to promote 3R methods primarily by confirming their scientific validity
- From 1991 to 2009 ECVAM was hosted within one JRC scientific Unit of the former Environment Institute (1991-1998) and of the Institute for Health and Consumer Protection (1998-2008)
- Since 2009 ECVAM is a Centre hosted by the Institute for Health and Consumer Protection and is served by mainly two scientific Units
- ECVAM has its own scientific advisory committee (ESAC)

ECVAM

- So far developed/optimised and/or validated 34 methods alternative to animal testing according to generally accepted validation principles
- Most methods have similar toxicological endpoints, i.e. skin and eye irritation; many methods are not replacement methods
- Maintains a database on alternative test methods (DB-ALM)
- Promotes method development through own research as well as through participation in RTD projects that will yield new methods
- Contributes to the regulatory acceptance of alternative methods

ECVAM's MISSION STATEMENT


To support the EU policies in the field of Consumer protection, Environmental protection and Animal protection

by validating alternative methods for safety testing that implement the 3Rs and provide the same or a better basis for risk assessment and risk management as current methods

and by promoting their development, their application in industry and their acceptance by regulators.

OUTLINE

- History
- **Validation principles**
- Successes and next challenges
- ECVAM Role



Information requirements that validation studies endeavour to satisfy

Test method definition

Module 1 – Test definition: **test system, SOP, prediction model, development, possible use, limitations, etc.**

Reliability Concordance/ Discordance

Module 2 – Within laboratory reproducibility: **sufficiently standardized to give reproducible results in one lab ?**

Module 3 – Transferability: **transferable, and yes, how readily?**

Module 4 – Between laboratory reproducibility: **how reproducible between labs?**

(Predictive) Relevance Accuracy

Module 5 – Predictive capacity: **Specificity, Sensitivity, Overall Accuracy**

Module 6 – Applicability domain/Limitations: **Which xenobiotics can NOT be tested?**

Performance criteria

Module 7 – Performance Standards: **Performance Acceptance Criteria for new tests that are sufficiently similar to the validated one**

OUTLINE

- History
- Validation principles
- **Successes and next challenges**
- ECVAM Role

**ECVAM activities & involvement,
Per endpoint, 2009**

| | Development | Prevalidation | Validation | Reg. acceptance | Post-reg. acceptance |
|---|-------------|---------------|------------|-----------------|----------------------|
| Skin Corrosion | ✓ | ✓ | ✓ | ✓ | ✓ |
| Acute Phototoxicity | ✓ | ✓ | ✓ | ✓ | |
| Skin Absorption / Penetration | ✓ | ✓ | ✓ | ✓ | |
| Skin Irritation | ✓ | ✓ | ✓ | ✓ | ✓ |
| Eye Irritation | ✓ | ✓ | ✓ * | ✓ * | |
| Acute Toxicity | ✓ | ✓ | ✓ * | | ✓ * |
| Genotoxicity / Mutagenicity | ✓ | ✓ | ✓ * | ✓ * | ✓ * |
| Skin Sensitisation | ✓ | ✓ | ✓ * | ✓ * | ✓ * |
| Reproductive & Developmental | ✓ | ✓ | ✓ * | ✓ * | |
| Toxicokinetics / Metabolism | ✓ | ✓ | ✓ * | | |
| Carcinogenicity | ✓ | ✓ * | ✓ * | | |
| Subacute & Subchronic Toxicity | ✓ | | | | |
| Biologicals, vaccines | ✓ | ✓ | ✓ | ✓ | ✓ |

* Reduction / refinement alternatives

Skin Corrosion


Acute Phototoxicity

Skin Absorption / Penetration

Skin Irritation

Photogenotoxicity

Eye Irritation



Acute Toxicity

Genotoxicity / Mutagenicity

Subacute & Subchronic Toxicity

Skin Sensitisation

Photo-allergy (-sensitisation)


Carcinogenicity-Toxicokinetics & Metabolism

Reproductive & Developmental Toxicity

Biggest challenge


Systemic Toxicity - Systems Biology

- Metabolism
- Multiple modes of action
- Dose/response
- One to one replacement not possible
- Battery of test methods
- Tiered testing strategies
- Combination of disciplines (*in vitro/in silico/in vivo/PBPK models*)
- **Integrated testing strategies**



New/emerging technologies

- Human cell-based metabolically competent liver cells
- Human stem cell-derived neurons/micro electrode arrays
- 3D in vitro tissue models
- Automation of in vitro methods (HTS/HCS)
- Development of computational methodology (in silico, QSAR)
- ‘Omics’, genomics, proteomics, metabonomics



EC Call for proposals on Alternative Testing Strategies in field of repeated dose systemic toxicity– 7th Framework programme

- COLIPA matched funding to EC (Eur 25 + 25 million)
- Open call – 30 July 2009 to 3 Feb 2010

Validation of Integrated Testing Strategies?

- Validate ITS or Building blocks of ITS or both?
- Building blocks (reliability (modules 1-4) sufficient?)
- Predictive capacity – validate against what?
- Validation should be ‘fit for purpose’
- Need case studies

Overcoming Barriers to Validation of Non-animal Partial replacement


Methods/Integrated testing Strategies: The Report of an EPAA-ECVAM Workshop.

ATLA, 37,437-444,2009

OUTLINE


- History
- Validation principles
- Successes and next challenges
- **ECVAM Role**

JRC-IHCP Units Supporting ECVAM







ECVAM has now full access to the broad range of competencies available across the Institute.




The relevant competencies include:

- at cellular level: in vitro methods, working with many different (human) cell systems and their automation towards high throughput;
- at sub-cellular level: "omics" (metabonomics, genomics);
- at molecular or chemical level: computational chemistry including QSAR.




PBPK and modeling expertise to help connect the cellular and sub-cellular levels with the organ or organism level.

Wealth of experience on validation of alternative methods







Validating alternative methods that provide the same or better basis for risk assessment as current methods




INNOVATION: contribute to methods/testing strategies that reduce reliance on in vivo animal studies even for complex endpoints



VALIDATION: continue to manage and coordinate scientific validation of submitted methods, assessing robustness, reliability, predictive capacity of methods and regulatory relevance, promoting regulatory acceptance











COMMUNICATION: engage with regulators/risk assessors, test developers, test users/risk assessors, promote dialogue/cross talk through workshops, promote uptake of methods through dissemination



Concluding remarks

- Integrated testing strategies required to address complex endpoints
- Emerging technologies give opportunity to make a gear change in progress
- A major challenge lies in the integration of the data and its interpretation in relation to specific regulatory questions
- Risk assessors need to engage in dialogue to give a steer to increase chance of relevant outcomes (both development and validation aspects)



*Alternative Methods to Animal Testing:
Improving the Scientific Basis for the Protection
of Human Health and the Environment while
Reducing the Need for Animal Testing*



for more information visit
<http://ecvam.jrc.ec.europa.eu/>

This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.